Kaposi sarcoma / Multiple hemorrhagic sarcoma

Oral Manifestations of HIV/AIDS
Dr. Patsy K. Fujimoto
http://www.hawaii.edu/

Kaposi’s sarcoma and AIDS-related malignancy
http://biology.ucsd.edu/

Kaposi's sarcoma (KS)
http://www.dentistry.unc.edu

Human Herpesvirus
Krystle Jones
http://ruby.fgcu.edu

Kaposi’s Sarcoma
Michael Hohnadel
http://www.atsu.edu

Human Herpesvirus Infections
Asmita Gupte, M.D.
http://www.mgm.ufl.edu

Oncogenic Viruses
http://biology.fullerton.edu

Kaposi’s Sarcoma
John O. Clarke, M.D.
http://oac.med.jhmi.edu/

Hypothetical new cancer therapy.
Esa K. Crumb
http://www.colorado.edu/

Castleman’s Disease
Anastassia Doutova
http://www.med.unc.edu/


264 free full text published articles of Kaposi sarcoma

1. [Coexistence of plasmablastic lymphoma, Kaposi sarcoma and Castleman disease in a patient with HIV infection].
2. [Conjunctival Kaposi sarcoma].
3. [Lymph node involvement in classic Kaposi sarcoma: report of three cases].
4. [Primary digestive tract Kaposi sarcoma with idiopathic CD4+ lymphocytopenia, HIV negative, HHV8 positive].
5. [The HIV nef and the Kaposi-sarcoma-associated virus K3/K5 proteins: "parasites"of the endocytosis pathway].
6. 1 Alpha,25-dihydroxyvitamin D3 and its TX527 analog inhibit the growth of endothelial cells transformed by Kaposi sarcoma-associated herpes virus G protein-coupled receptor in vitro and in vivo.
7. A Bcl-2 homolog encoded by Kaposi sarcoma-associated virus, human herpesvirus 8, inhibits apoptosis but does not heterodimerize with Bax or Bak.
8. A case of classic Kaposi sarcoma in a 11-year-old male.
9. A case of Kaposi sarcoma mimicking nephrogenic systemic fibrosis.
10. A common genetic variant in FCGR3A-V158F and risk of Kaposi sarcoma herpesvirus infection and classic Kaposi sarcoma.
11. A pilot study of cidofovir in patients with kaposi sarcoma.
12. A single 13-kilobase divergent locus in the Kaposi sarcoma-associated herpesvirus (human herpesvirus 8) genome contains nine open reading frames that are homologous to or related to cellular proteins.
13. A WT1 expressing metastatic human Kaposi sarcoma xenograft model.
14. A20 is induced by Kaposi sarcoma-associated herpesvirus-encoded viral FLICE inhibitory protein (vFLIP) K13 and blocks K13-induced nuclear factor-kappaB in a negative feedback manner.
15. Absence of biologically important Kaposi sarcoma-associated herpesvirus gene products and virus-specific cellular immune responses in multiple myeloma.
16. Acroangiodermatitis (pseudo-Kaposi sarcoma): a rarely-recognized condition. A case on the plantar aspect of the foot associated with chronic venous insufficiency.
17. Activation of Src kinase Lyn by the Kaposi sarcoma-associated herpesvirus K1 protein: implications for lymphomagenesis.
18. Activity of subcutaneous interleukin-12 in AIDS-related Kaposi sarcoma.
19. Acute graft dysfunction due to Kaposi sarcoma involving the bladder in a renal transplant recipient.
20. AIDS Kaposi sarcoma-derived cells produce and respond to interleukin 6.
21. AIDS-Kaposi Sarcoma and Classic Kaposi Sarcoma: are different ultrasound patterns related to different variants?
22. AIDS-related Kaposi sarcoma: findings on thallium-201 scintigraphy.
23. Alimentary tract involvement in Kaposi sarcoma: radiographic and endoscopic findings in 25 homosexual men.
24. An IL6 promoter polymorphism is associated with a lifetime risk of development of Kaposi sarcoma in men infected with human immunodeficiency virus.
25. An interleukin-6-related systemic inflammatory syndrome in patients co-infected with Kaposi sarcoma-associated herpesvirus and HIV but without Multicentric Castleman disease.
26. Anaplastic Kaposi sarcoma resembling epithelioid angiosarcoma in an HIV-positive man.
27. Antitumorigenic effects of HIV protease inhibitor ritonavir: inhibition of Kaposi sarcoma.
28. Arabs and kaposi sarcoma.
29. Associations of classic Kaposi sarcoma with common variants in genes that modulate host immunity.
30. B-Raf-dependent expression of vascular endothelial growth factor-A in Kaposi sarcoma-associated herpesvirus-infected human B cells.
31. Caspase-7 cleavage of Kaposi sarcoma-associated herpesvirus ORF57 confers a cellular function against viral lytic gene expression.
32. CD4(+) and CD8(+) T-Cell Skewness in Classic Kaposi Sarcoma.
33. CD68+ cells of monocyte/macrophage lineage in the environment of AIDS-associated and classic-sporadic Kaposi sarcoma are singly or doubly infected with human herpesviruses 7 and 6B.
34. Characterization of Kaposi sarcoma-associated herpesvirus/human herpesvirus-8 infection of human vascular endothelial cells: early events.
35. Classic Kaposi sarcoma in 3 unrelated Turkish children born to consanguineous kindreds.
36. Classic Kaposi Sarcoma in the United States over the last two decades: a clinicopathologic and molecular study of 438 non-HIV-related Kaposi Sarcoma patients with comparison to HIV-related Kaposi Sarcoma.
37. Classic Kaposi sarcoma mimicking chilblains.
38. Classic Kaposi sarcoma.
39. Classic Kaposi sarcoma. Which KSHV-seropositive individuals are at risk?
40. Classical Kaposi sarcoma: prognostic factor analysis of 248 patients.
41. Clinical Manifestations of Kaposi Sarcoma Herpesvirus Lytic Activation: Multicentric Castleman Disease (KSHV-MCD) and the KSHV Inflammatory Cytokine Syndrome.
42. Clinical presentation and outcome of epidemic Kaposi sarcoma in Ugandan children.
43. Coexistent gastric MALT lymphoma and Kaposi sarcoma in an HIV positive patient.
44. Comparative pathobiology of Kaposi sarcoma-associated herpesvirus and related primate rhadinoviruses.
45. Complex N-linked glycans on Asn-89 of Kaposi sarcoma herpes virus-encoded interleukin-6 mediate optimal function by affecting cytokine protein conformation.
46. Conjunctival regressing Kaposi sarcoma.
47. Conservation of virally encoded microRNAs in Kaposi sarcoma--associated herpesvirus in primary effusion lymphoma cell lines and in patients with Kaposi sarcoma or multicentric Castleman disease.
48. Constitutively active K-cyclin/cdk6 kinase in Kaposi sarcoma-associated herpesvirus-infected cells.
49. Correlates of Human Herpesvirus-8 DNA detection among adults in Italy without Kaposi sarcoma.
50. Cutaneous Kaposi sarcoma which developed in a patient with aplastic anaemia using immunosuppressive therapy--description of the first adult case.
51. Cyclin D1 expression and HHV8 in Kaposi sarcoma.
52. De novo Renal Transplantation after Kaposi Sarcoma: Favorable Outcome in a Patient Receiving Sirolimus and Mycophenolate-Based Immunosuppression.
53. Delayed-type hypersensitivity in classic Kaposi sarcoma patients and controls.
54. Detection of herpesvirus-like DNA by nested PCR on archival skin biopsy specimens of various forms of Kaposi sarcoma.
55. Detection of kaposi sarcoma-associated herpesvirus DNA in saliva and buffy-coat samples from children with sickle cell disease in Uganda.
56. Detection of viral interleukin-6 in Kaposi sarcoma-associated herpesvirus-linked disorders.
57. Differences in androgens of HIV positive patients with and without Kaposi sarcoma.
58. Differences in the frequency and function of HHV8-specific CD8 T cells between asymptomatic HHV8 infection and Kaposi sarcoma.
59. Distinct profiles of antibodies to Kaposi sarcoma-associated herpesvirus antigens in patients with Kaposi sarcoma, multicentric Castleman disease, and primary effusion lymphoma.
60. Distribution of Kaposi sarcoma-associated herpesvirus/human herpesvirus 8 in maternal saliva and breast milk in Zambia: implications for transmission.
61. Editorial commentary: treatment of Kaposi sarcoma in the highly active antiretroviral therapy era.
62. Efficacy of 5% imiquimod cream in a patient with classic Kaposi sarcoma.
63. Environmental factors influence the rate of human herpesvirus type 8 infection in a population with high incidence of classic Kaposi sarcoma.
64. Ephrin B2 expression in Kaposi sarcoma is induced by human herpesvirus type 8: phenotype switch from venous to arterial endothelium.
65. Evaluation of plasma human herpesvirus 8 DNA as a marker of clinical outcomes during antiretroviral therapy for AIDS-related Kaposi sarcoma in Zimbabwe.
66. Evidence for a multiclonal origin of multicentric advanced lesions of Kaposi sarcoma.
67. Expression of platelet-derived growth factor and its receptor in AIDS-related Kaposi sarcoma in vivo suggests paracrine and autocrine mechanisms of tumor maintenance.
68. Familial clustering of classic Kaposi sarcoma.
69. Fatal pneumocystis pneumonia, cryptococcosis, and Kaposi sarcoma in a homosexual man.
70. Gender differences in clinical presentation and outcomes of epidemic Kaposi sarcoma in Uganda.
71. Geographic variation in the prevalence of Kaposi sarcoma-associated herpesvirus and risk factors for transmission.
72. Glycyrrhizic acid alters Kaposi sarcoma-associated herpesvirus latency, triggering p53-mediated apoptosis in transformed B lymphocytes.
73. Hemorrhagic Kaposi sarcoma. Successful treatment with IFN-alpha.
74. Hepatitis B virus DNA in Kaposi sarcoma.
75. Herpes virus-like sequences are specifically found in Kaposi sarcoma lesions.
76. HHV-8 positive Kaposi sarcoma in a patient with end-stage renal disease undergoing hemodialysis: no regressive effect of captopril.
77. High conservation of Kaposi sarcoma--associated herpesvirus microRNAs implies important function.
78. High incidence of Kaposi sarcoma-associated herpesvirus-related non-Hodgkin lymphoma in patients with HIV infection and multicentric Castleman disease.
79. High-dose zidovudine plus valganciclovir for Kaposi sarcoma herpesvirus-associated multicentric Castleman disease: a pilot study of virus-activated cytotoxic therapy.
80. Histological variants of cutaneous Kaposi sarcoma.
81. Histopathological analysis of vesicular and bullous lesions in Kaposi sarcoma.
82. HIV/AIDS: epidemiology, pathophysiology, and treatment of Kaposi sarcoma-associated herpesvirus disease: Kaposi sarcoma, primary effusion lymphoma, and multicentric Castleman disease.
83. HIV-1 Tat enhances Kaposi sarcoma-associated herpesvirus (KSHV) infectivity.
84. HLA polymorphisms and detection of kaposi sarcoma-associated herpesvirus DNA in saliva and peripheral blood among children and their mothers in the uganda sickle cell anemia KSHV Study.
85. Human bcl-2 expression, cleaved caspase-3, and KSHV LANA-1 in Kaposi sarcoma lesions.
86. Human Herpesvirus 8 (HHV8) sequentially shapes the NK cell repertoire during the course of asymptomatic infection and Kaposi sarcoma.
87. Human herpesvirus 8 and iron staining are useful in differentiating Kaposi sarcoma from interstitial granuloma annulare.
88. Human herpesvirus 8 genotype E in patients with Kaposi sarcoma, Peru.
89. Human herpesvirus 8 immunostaining: a sensitive and specific method for diagnosing Kaposi sarcoma in paraffin-embedded sections.
90. Human herpesvirus 8 load and progression of AIDS-related Kaposi sarcoma lesions.
91. Human herpesvirus 8 variants in Venezuelan patients with AIDS-related Kaposi sarcoma.
92. Human herpesvirus-8 and Kaposi sarcoma after kidney transplantation: mechanisms of tumor genesis.
93. Human Herpesvirus-8 Infection Associated with Kaposi Sarcoma, Multicentric Castleman's Disease, and Plasmablastic Microlymphoma in a Man with AIDS: A Case Report with Review of Pathophysiologic Processes.
94. Human immunodeficiency virus type 1 Tat accelerates Kaposi sarcoma-associated herpesvirus Kaposin A-mediated tumorigenesis of transformed fibroblasts in vitro as well as in nude and immunocompetent mice.
95. Hypoxia induces lytic replication of Kaposi sarcoma-associated herpesvirus.
96. Hypoxia-inducible factor-1alpha and hypoxia-inducible factor-2alpha are expressed in kaposi sarcoma and modulated by insulin-like growth factor-I.
97. Identification of caspase-mediated decay of interferon regulatory factor-3, exploited by a Kaposi sarcoma-associated herpesvirus immunoregulatory protein.
98. IFI16 acts as a nuclear pathogen sensor to induce the inflammasome in response to Kaposi Sarcoma-associated herpesvirus infection.
99. Imaging features of pulmonary Kaposi sarcoma-associated immune reconstitution syndrome.
100. Imaging manifestations of Kaposi sarcoma.
101. Immune reconstitution inflammatory syndrome associated with Kaposi sarcoma during potent antiretroviral therapy.
102. Immunohistochemical detection of human herpes virus-8 latent nuclear antigen-1 is useful in the diagnosis of Kaposi sarcoma.
103. Immunostaining for CD31 and CD34 in Kaposi sarcoma.
104. Immunostaining for human herpesvirus 8 latent nuclear antigen-1 helps distinguish Kaposi sarcoma from its mimickers.
105. Impact of highly active antiretroviral therapy on the presenting features and outcome of patients with acquired immunodeficiency syndrome-related Kaposi sarcoma.
106. Impact of HIV infection and Kaposi sarcoma on human herpesvirus-8 mucosal replication and dissemination in Uganda.
107. Impact of Kaposi sarcoma-associated herpesvirus (KSHV) burden and HIV coinfection on the detection of T cell responses to KSHV ORF73 and ORF65 proteins.
108. Induction of CCL20 production by Kaposi sarcoma-associated herpesvirus: role of viral FLICE inhibitory protein K13-induced NF-kappaB activation.
109. Induction, regulation, and biologic function of Axl receptor tyrosine kinase in Kaposi sarcoma.
110. Inefficient establishment of KSHV latency suggests an additional role for continued lytic replication in Kaposi sarcoma pathogenesis.
111. Influence of HLA alleles on shedding of Kaposi sarcoma-associated herpesvirus in saliva in an African population.
112. Inhibition of heme oxygenase-1 interferes with the transforming activity of the Kaposi sarcoma herpesvirus-encoded G protein-coupled receptor.
113. Insights into pathogenic events of HIV-associated Kaposi sarcoma and immune reconstitution syndrome related Kaposi sarcoma.
114. Intestinal parasites in Kaposi sarcoma patients in Uganda: indication of shared risk factors or etiologic association.
115. Intrabodies targeting the Kaposi sarcoma-associated herpesvirus latency antigen inhibit viral persistence in lymphoma cells.
116. Isolated Kaposi Sarcoma in two HIV negative patients.
117. Isolation of a rearranged human transforming gene following transfection of Kaposi sarcoma DNA.
118. Kaposi sarcoma (KS)-associated herpesvirus microRNA sequence analysis and KS risk in a European AIDS-KS case control study.
119. Kaposi sarcoma after corticosteroid therapy for idiopathic thrombocytopenic purpura.
120. Kaposi sarcoma after kidney transplantation.
121. Kaposi sarcoma and gonadoblastoma dysgerminoma with gonadal dysgenesis following cadaveric renal transplantation.
122. Kaposi sarcoma herpes virus-associated hemophagocytic syndrome complicated by multicentric castleman disease and kaposi sarcoma in a HIV-negative immunocompetent patient: an autopsy case.
123. Kaposi sarcoma herpesvirus (KSHV) vFLIP oncoprotein induces B cell transdifferentiation and tumorigenesis in mice.
124. Kaposi sarcoma herpesvirus K5 removes CD31/PECAM from endothelial cells.
125. Kaposi sarcoma herpesvirus-encoded vFLIP and vIRF1 regulate antigen presentation in lymphatic endothelial cells.
126. Kaposi sarcoma in a HIV uninfected man who has sex with men.
127. Kaposi Sarcoma in a Non HIV Patient.
128. Kaposi sarcoma in a paediatric renal transplant recipient.
129. Kaposi sarcoma in calabar, southern Nigeria.
130. Kaposi sarcoma in Germany.
131. Kaposi sarcoma in kidney transplanted patients.
132. Kaposi sarcoma in the external ear.
133. Kaposi sarcoma in the setting of cushing disease.
134. Kaposi sarcoma in unusual locations.
135. Kaposi sarcoma incidence and survival among HIV-infected homosexual men after HIV seroconversion.
136. Kaposi sarcoma incidence in the Swiss HIV Cohort Study before and after highly active antiretroviral therapy.
137. Kaposi sarcoma involving the gastrointestinal tract.
138. Kaposi sarcoma is a therapeutic target for vitamin D(3) receptor agonist.
139. Kaposi sarcoma of lymph nodes.
140. Kaposi sarcoma of the adrenal gland resembling epithelioid angiosarcoma: a case report.
141. Kaposi sarcoma of the lung.
142. Kaposi sarcoma of the musculoskeletal system: a review of 66 patients.
143. Kaposi sarcoma of the stomach: a case report.
144. Kaposi sarcoma of the ureter after liver transplant: case report and literature review.
145. Kaposi sarcoma presenting as severe haemoptysis.
146. Kaposi sarcoma: appraisal of therapeutic agents.
147. Kaposi sarcoma: changing trend in Calabar, south eastern Nigeria.
148. Kaposi sarcoma-associated herpes virus (KSHV) G protein-coupled receptor (vGPCR) activates the ORF50 lytic switch promoter: a potential positive feedback loop for sustained ORF50 gene expression.
149. Kaposi sarcoma-associated herpes virus targets the lymphotactin receptor with both a broad spectrum antagonist vCCL2 and a highly selective and potent agonist vCCL3.
150. Kaposi sarcoma-associated herpes-like virus (human herpesvirus type 8) DNA sequences in multicentric Castleman's disease: is there any relevant association in non-human immunodeficiency virus-infected patients?
151. Kaposi sarcoma-associated herpesvirus (KSHV) induces heme oxygenase-1 expression and activity in KSHV-infected endothelial cells.
152. Kaposi sarcoma-associated herpesvirus (KSHV) seroprevalence in population-based samples of African children: evidence for at least 2 patterns of KSHV transmission.
153. Kaposi sarcoma-associated herpesvirus degrades cellular Toll-interleukin-1 receptor domain-containing adaptor-inducing beta-interferon (TRIF).
154. Kaposi sarcoma-associated herpesvirus infects monotypic (IgM lambda) but polyclonal naive B cells in Castleman disease and associated lymphoproliferative disorders.
155. Kaposi sarcoma-associated herpesvirus latency-associated nuclear antigen inhibits interferon (IFN) beta expression by competing with IFN regulatory factor-3 for binding to IFNB promoter.
156. Kaposi sarcoma-associated herpesvirus serum DNA and antibodies not associated with subsequent non-Hodgkin lymphoma risk.
157. Kaposi sarcoma-associated herpesvirus/human herpesvirus 8 and lymphoproliferative disorders.
158. Kaposi sarcoma-associated herpesvirus-encoded viral FLICE inhibitory protein (vFLIP) K13 cooperates with Myc to promote lymphoma in mice.
159. Kaposi sarcoma-associated viral cyclin K overrides cell growth inhibition mediated by oncostatin M through STAT3 inhibition.
160. Kaposi sarcoma-like multinucleate cell angiohistiocytoma complicating an iatrogenic arteriovenous fistula.
161. KSHV and the pathogenesis of Kaposi sarcoma: listening to human biology and medicine.
162. Large mass arising from the tongue as an initially and sole manifestation of Kaposi sarcoma.
163. Latency-associated nuclear antigen expression and human herpesvirus-8 polymerase chain reaction in the evaluation of Kaposi sarcoma and other vascular tumors in HIV-positive patients.
164. Letter: Kaposi sarcoma versus nephrogenic systemic fibrosis.
165. Letter: Penile Kaposi sarcoma: A case of complete resolution with highly active antiretroviral therapy alone.
166. Long-term prognosis of HIV-infected patients with Kaposi sarcoma treated with pegylated liposomal doxorubicin.
167. Long-term remission of Kaposi sarcoma-associated herpesvirus-related multicentric Castleman disease with anti-CD20 monoclonal antibody therapy.
168. Low T cell responses to human herpesvirus 8 in patients with AIDS-related and classic Kaposi sarcoma.
169. Lymphangioscintigraphy in AIDS-associated Kaposi sarcoma.
170. Lytic replication-associated protein (RAP) encoded by Kaposi sarcoma-associated herpesvirus causes p21CIP-1-mediated G1 cell cycle arrest through CCAAT/enhancer-binding protein-alpha.
171. Mechanism of sustained activation of ribosomal S6 kinase (RSK) and ERK by kaposi sarcoma-associated herpesvirus ORF45: multiprotein complexes retain active phosphorylated ERK AND RSK and protect them from dephosphorylation.
172. Molecular and clinical assessment in the treatment of AIDS Kaposi sarcoma with valproic Acid.
173. Molecular evidence for mother-to-child transmission of Kaposi sarcoma-associated herpesvirus in Uganda and K1 gene evolution within the host.
174. Molecular evidence of organ-related transmission of Kaposi sarcoma-associated herpesvirus or human herpesvirus-8 in transplant patients.
175. Moving toward clarity on 2 fronts in the epidemiology of Kaposi sarcoma-associated herpesvirus infection.
176. Multicenter trial of low-dose paclitaxel in patients with advanced AIDS-related Kaposi sarcoma.
177. Nucleotide sequence of the Kaposi sarcoma-associated herpesvirus (HHV8).
178. Opposing regulation of PROX1 by interleukin-3 receptor and NOTCH directs differential host cell fate reprogramming by Kaposi sarcoma herpes virus.
179. Palatal Actinomycosis and Kaposi Sarcoma in an HIV-Infected Subject with Disseminated Mycobacterium avium-intracellulare Infection.
180. Pathology of rituximab-induced Kaposi sarcoma flare.
181. Pegylated liposomal doxorubicin as second-line therapy in the treatment of patients with advanced classic Kaposi sarcoma: a retrospective study.
182. Persistence of Kaposi sarcoma-associated herpesvirus (KSHV)-infected cells in KSHV/HIV-1-coinfected subjects without KSHV-associated diseases.
183. Persistent Kaposi sarcoma in the era of highly active antiretroviral therapy: characterizing the predictors of clinical response.
184. Phase 1/2 trial of BMS-275291 in patients with human immunodeficiency virus-related Kaposi sarcoma: a multicenter trial of the AIDS Malignancy Consortium.
185. Phase 2 study of pegylated liposomal doxorubicin in combination with interleukin-12 for AIDS-related Kaposi sarcoma.
186. Phase II AIDS Malignancy Consortium trial of topical halofuginone in AIDS-related Kaposi sarcoma.
187. Pilot study of oral valganciclovir therapy in patients with classic Kaposi sarcoma.
188. Polyadenylylated nuclear RNA encoded by Kaposi sarcoma-associated herpesvirus.
189. Poor specific T cell responses to human herpesvirus 8: A key to unleashing Kaposi sarcoma?
190. Pre- and posttreatment MR imaging in AIDS-related Kaposi sarcoma of the conjunctiva and lacrimal gland.
191. Pre-micro RNA signatures delineate stages of endothelial cell transformation in Kaposi sarcoma.
192. Prevalence and predictors of kaposi sarcoma herpes virus seropositivity: a cross-sectional analysis of HIV-infected adults initiating ART in Johannesburg, South Africa.
193. Primary Kaposi sarcoma of the subcutaneous tissue.
194. Proceedings: Kaposi sarcoma in African children.
195. Prognostic value of quantitative Kaposi sarcoma--associated herpesvirus load in posttransplantation Kaposi sarcoma.
196. Proximal Subungual Onychomycosis in a Patient with Classic Kaposi Sarcoma Caused by Trichophyton rubrum.
197. Pseudo-Kaposi sarcoma: a challenging vascular phenomenon.
198. Pulmonary features of Kaposi sarcoma.
199. Pulmonary involvement in Kaposi sarcoma: correlation between imaging and pathology.
200. Pulmonary Kaposi sarcoma in a human immunodeficiency virus - infected woman: a case report.
201. Purple-blue subcutaneous nodules after renal transplantation: not always Kaposi sarcoma.
202. Pyogenic granuloma-like Kaposi sarcoma: a diagnostic pitfall.
203. Quantitative analysis of Kaposi sarcoma-associated herpesvirus (KSHV) in KSHV-associated diseases.
204. Radiographic patterns of opportunistic lung infections and Kaposi sarcoma in homosexual men.
205. Randomized trial of paclitaxel versus pegylated liposomal doxorubicin for advanced human immunodeficiency virus-associated Kaposi sarcoma: evidence of symptom palliation from chemotherapy.
206. Receptor engagement by viral interleukin-6 encoded by Kaposi sarcoma-associated herpesvirus.
207. Reconstitution of immune responses against Kaposi sarcoma-associated herpesvirus.
208. Reduced levels of neutralizing antibodies to Kaposi sarcoma-associated herpesvirus in persons with a history of Kaposi sarcoma.
209. Regression of post-transplant Kaposi sarcoma after discontinuing cyclosporin and giving mycophenolate mofetil instead.
210. Regulation of microfilament organization by Kaposi sarcoma-associated herpes virus-cyclin.CDK6 phosphorylation of caldesmon.
211. Relationship between the quantity of Kaposi sarcoma-associated herpesvirus (KSHV) in peripheral blood and effusion fluid samples and KSHV-associated disease.
212. Relationship of Kaposi sarcoma (KS)-associated herpesvirus viremia and KS disease in Zimbabwe.
213. Requirement of UAP56, URH49, RBM15, and OTT3 in the expression of Kaposi sarcoma-associated herpesvirus ORF57.
214. Restricted expression of Kaposi sarcoma-associated herpesvirus (human herpesvirus 8) genes in Kaposi sarcoma.
215. Risk factors for classical Kaposi sarcoma in a population-based case-control study in Sicily.
216. Risk of classic Kaposi sarcoma with exposures to plants and soils in Sicily.
217. Risk of classic Kaposi sarcoma with residential exposure to volcanic and related soils in Sicily.
218. Risk of classical Kaposi sarcoma by plasma levels of Epstein-Barr virus antibodies, sCD26, sCD23 and sCD30.
219. Role of scatter factor in the pathogenesis of AIDS-related Kaposi sarcoma.
220. Rta of the human herpesvirus 8/Kaposi sarcoma-associated herpesvirus up-regulates human interleukin-6 gene expression.
221. Secondary involvement of lymph nodes in Kaposi sarcoma.
222. Selective expression of stromal-derived factor-1 in the capillary vascular endothelium plays a role in Kaposi sarcoma pathogenesis.
223. Seroprevalence of Kaposi sarcoma-associated herpesvirus and other serologic markers in the Brazilian Amazon.
224. Simultaneous Hodgkin's disease and Kaposi sarcoma in a renal transplant recipient.
225. Socio-economic and other correlates of Kaposi sarcoma-associated herpesvirus seroprevalence among older adults in Sicily.
226. Solitary laryngeal Kaposi sarcoma in a kidney transplant patient.
227. Solution structure of a Bcl-2 homolog from Kaposi sarcoma virus.
228. Stimulation of c-Myc transcriptional activity by vIRF-3 of Kaposi sarcoma-associated herpesvirus.
229. Strain variability among Kaposi sarcoma-associated herpesvirus (human herpesvirus 8) genomes: evidence that a large cohort of United States AIDS patients may have been infected by a single common isolate.
230. Structural and functional analyses of Kaposi sarcoma-associated herpesvirus ORF57 nuclear localization signals in living cells.
231. Susceptibility of human fetal mesenchymal stem cells to Kaposi sarcoma-associated herpesvirus.
232. Systematic identification of cellular signals reactivating Kaposi sarcoma-associated herpesvirus.
233. Targeted inhibition of calcineurin signaling blocks calcium-dependent reactivation of Kaposi sarcoma-associated herpesvirus.
234. Targeted therapy for Kaposi sarcoma.
235. Thallium scan in the detection of Kaposi sarcoma.
236. The changing pattern of Kaposi sarcoma in patients with HIV, 1994-2003: the EuroSIDA Study.
237. The chemokine receptor CCR8 mediates human endothelial cell chemotaxis induced by I-309 and Kaposi sarcoma herpesvirus-encoded vMIP-I and by lipoprotein(a)-stimulated endothelial cell conditioned medium.
238. The dialysed patient with both Castleman disease and Kaposi sarcoma.
239. The epigenetic landscape of latent Kaposi sarcoma-associated herpesvirus genomes.
240. The extraordinary hope of antiretroviral therapy in South Africa (even for patients with tuberculosis or kaposi sarcoma!).
241. The Galpha12/13 family of heterotrimeric G proteins and the small GTPase RhoA link the Kaposi sarcoma-associated herpes virus G protein-coupled receptor to heme oxygenase-1 expression and tumorigenesis.
242. The Kaposi sarcoma-associated herpesvirus (KSHV) induces cellular interleukin 6 expression: role of the KSHV latency-associated nuclear antigen and the AP1 response element.
243. The Kaposi sarcoma-associated herpesvirus (KSHV) is present as an intact latent genome in KS tissue but replicates in the peripheral blood mononuclear cells of KS patients.
244. The latency-associated nuclear antigen of Kaposi sarcoma-associated herpesvirus induces B cell hyperplasia and lymphoma.
245. The malignant potential of HIV-associated Kaposi sarcoma.
246. The origin of Kaposi sarcoma.
247. The prognostic significance of facial lymphoedema in HIV-seropositive subjects with Kaposi sarcoma.
248. The role of Ephs, Ephrins, and growth factors in Kaposi sarcoma and implications of EphrinB2 blockade.
249. The small GTPase Rac1 links the Kaposi sarcoma-associated herpesvirus vGPCR to cytokine secretion and paracrine neoplasia.
250. The Tat protein of human immunodeficiency virus type 1, a growth factor for AIDS Kaposi sarcoma and cytokine-activated vascular cells, induces adhesion of the same cell types by using integrin receptors recognizing the RGD amino acid sequence.
251. Thymidine phosphorylase expression in Kaposi sarcoma.
252. Toll-like receptor 4 mediates innate immunity to Kaposi sarcoma herpesvirus.
253. Total skin electron treatment of extensive cutaneous lesions in Kaposi sarcoma.
254. Treatment of Kaposi sarcoma-associated herpesvirus-associated cancers.
255. Treatment with taxanes of refractory or life-threatening Kaposi sarcoma not associated with human immunodeficiency virus infection.
256. Tumor suppressor microRNAs are underrepresented in primary effusion lymphoma and Kaposi sarcoma.
257. Unusual site of kaposi sarcoma after kidney transplantation.
258. Update on KSHV epidemiology, Kaposi Sarcoma pathogenesis, and treatment of Kaposi Sarcoma.
259. Variable clinical presentations of Classic Kaposi Sarcoma in Turkish patients.
260. Vascular endothelial growth factor/vascular permeability factor is an autocrine growth factor for AIDS-Kaposi sarcoma.
261. Viral oncogene-induced DNA damage response is activated in Kaposi sarcoma tumorigenesis.
262. Virologic, hematologic, and immunologic risk factors for classic Kaposi sarcoma.
263. Weekly docetaxel is safe and effective in the treatment of advanced-stage acquired immunodeficiency syndrome-related Kaposi sarcoma.
264. Whole-exome sequencing-based discovery of STIM1 deficiency in a child with fatal classic Kaposi sarcoma.